Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Management and Treatment of Hepatitis C Viral Infection: References

for Health Care Providers

References

  1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
  2. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005; 41:88-96.
  3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32.
  4. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002; 35:S72-8.
  5. CDC. Recommendations for prevention and control of hepatitis C virus HCV infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR 1998; 47:1-39.
  6. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36:S3-S20.
  7. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
  8. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manuel. San Antonio, TX: Psychological Corporation, 1996.
  9. The VA Hepatitis C Resource Center Program and National Hepatitis C Program Office VHA. Management of psychiatric and substance use disorders in patients with hepatitis C: A reference for hepatitis C care providers. 2005:1-36.
  10. NIAAA. The physician's guide to helping patients with alcohol problems. Bethesda, MD: National Institutes of Health, 1995:NIH publication number 95-3769.
  11. Rebetol®. Kenilworth, NJ: Schering Corporation, 2002.
  12. Pegasys®. Nutley, NJ: Hoffman-La Roche Inc, 2005.
  13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
  14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
  15. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-80.
  16. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
  17. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-71.
  18. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-52.
  19. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-8.
  20. Sanchez-Tapias J, Diago M, Enriquez J, et al. Longer treatment duration with peginterferon alfa-2a (40kd) (Pegasys®) and ribavirin (Copegus®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter Teravic-4 Study. Hepatology 2004; 40:218A.
  21. Berg T, von Wagner M HT, Buggisch P, et al. for the German Study Group PEGASYS + COPEGUS in HCV Genotype 1. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology 2005; 40:238A.
  22. Jensen DM, Morgan T, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40kd)/ribavirin therapy. Hepatology 2006; 43:454-60.
  23. Ferenci P, Bergholz U, Laferl H, et al. Is shorter treatment with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) possible in HCV genotype 1 'super-responders'? Preliminary results of a prospective randomized clinical trial. Hepatology 2005; 42:218A.
  24. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17.
  25. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
  26. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-9.
  27. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004; 40:1260-5.
  28. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:1164-72.
  29. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-13.
  30. Afdahl N, Freilich B, Levine R, et al. Colchicine versus PEG-Intron Long Term (COPILOT) Trial: Interim analysis of clinical outcomes at year 2. Hepatology 2004; 40:239A.
  31. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-23; discussion 947.
  32. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453-62.
  33. Poynard T, Schiff E, Terg R, et al. Sustained Virologic Response (SVR) In the EPIC3 Trial: Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PegIntron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005; 42:40.
  34. Leevy CC, Blatt, LM. Predictive model and sustained virologic response for PEG IFN-alfa-2 + weight-based ribavirin nonresponders re-treated with IFN alfacon-1 + weight-based ribavirin. Gastroenterology 2005; 128:A-715.
  35. Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C. Gut 2006 (epublication ahead of print).
  36. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36:S179-84.
  37. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-32.
  38. Thakeb FIA, Oman MM, Awady MM, et a. Randomized controlled tiral of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003, 38:738A.
  39. Diago M, Hassanein T, Rodes J, et al. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004; 140:72-3.
  40. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858-66.
  41. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-4.
  42. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002; 67:117-23.
  43. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-46.
  44. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol 2000; 35:296-301.
  45. Anand B, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study. Gastroenterology 2006; 130:1607-16.
  46. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38:75-85.
  47. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-90.
  48. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89-94.
  49. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292:2839-48.
  50. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
  51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
  52. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
  53. Darbepoetin. Thousand Oaks, CA: Amgen Manufacturing, Limited, 2004.
  54. Tien P, Wright T. Management and treatment of hepatitis C virus infection in HIV-infected adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J of Gastroenterol 2005; 100:1-17.
  55. Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000; 13:75-85.
  56. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11:1896-902.
  57. Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98:1610-5.
  58. Lamb M, Marks I, Wynohradnyk L, et al. 40 KDa peginterferon alfa-2a (Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology 2001; 34:326A.
  59. Russo M, Ghalib R, Sigal S, et al. A multi-center randomized trial of pegylated interferon alfa-2b monotherapy (Peg-Intron) in patients with chronic hepatitis C and end stage kidney disease on dialysis. Hepatology 2004; 40:399A.
  60. Peg-Intron®. Kenilworth, NJ: Schering Corporation, 2005.
  61. Copegus®. Nutley, NJ: Roche Pharmaceuticals, 2005.
  62. Jaeckel E, Markus C, Wedemeyer J, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J of Med 2001; 345:1452-7.
  63. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-8.
  64. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329-33.
  65. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721-31.
  66. Rocca P, Bailly F, Chevallier M, et al. Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients. Gastroenterol Clin Biol 2003; 27:294-9.
  67. Everson GT, J; Forman, L; Kugelmas, M; et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255-62.
  68. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9:S1-9.
  69. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7:181-90.
  70. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40:669-74.
  71. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41:289-98.
  72. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78:1303-7.
  73. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10:859-67.
  74. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
  75. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302-11.
  76. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1450-8.
  77. Epoetin. Thousand Oaks, CA: Amgen Inc, 2005.
  78. Procrit®. Raritan, NJ: Manufactured by Amgen Inc and distributed by Ortho Biotech Products, L.P., 2005.
  79. Ishizone S, Makuuchi M, Kawasaki S, et al. Effect of granulocyte colony-stimulating factor on neutropenia in liver transplant recipients with hypersplenism. J Pediatr Surg 1994; 29:510-3.
  80. Rolando N, Clapperton M, Wade J, et al. Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. Eur J Gastroenterol Hepatol 2000; 12:1323-8.
  81. Pardo M, Castillo I, Navas S, et al. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. J Med Virol 1995; 45:439-44.
  82. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273-9.
  83. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94:1918-22.
  84. Rustgi VK, Lee P, Fennegan S, et al. Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirin in hepatitis C patients with thrombocytopenia. Hepatology 2002; 36:361A.